Of all recent or potential regulatory issues, the move from fee-for-service to bundled or value-based payments has the biggest impact on dealmaking, according to a West Monroe and Mergermarket report.
Mergermarket surveyed 100 senior corporate and private equity executives from U.S. firms that had completed at least one healthcare deal in the past two years.
Here are seven statistics:
1. Move from fee-for-service to bundled/value-based payments: 19 percent
2. End of cost-sharing reduction payments to insurers: 18 percent
3. Repeal of the individual mandate: 16 percent
4. Possibility of new regulation to lower drug prices: 13 percent
5. Reduced Medicaid contributions to states: 13 percent
6. Uncertain future of the ACA: 11 percent
7. Reduced reimbursement on 340B qualified drugs: 10 percent